Heat Inactivated Poxvirus Improves Vaccination Results

• US 20170021009A1
• Filed: 03/10/2015
• Published: 01/26/2017
• Est. Priority Date: 03/10/2014
• Status: Abandoned Application

• Current Assignee: Arizona Board of Regents (University of Arizona)
• Original Assignee: Arizona Board of Regents (University of Arizona)
• Inventors: Huynh, Trung, Blattman, Negin, Dumbell, Keith, Jacobs, Bertram
• Application Number:
  US15/125,024
• Publication Number:
  US 20170021009A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/525 Virus
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/285 Vaccinia virus or variola virus
• CPC Class Codes: C12N 2710/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/24161 Methods of inactivation or attenuation
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

Compositions including a heat-inactivated poxvirus, such as vaccinia virus, that induces one or more interferons in a vaccine recipient. The compositions may further include one or more live vaccine vectors and non-replicating vaccine components. Methods of vaccine preparation and administration including a heat-inactivated poxvirus, such as vaccinia virus, improve vaccine immunogenicity and safety.

Claims

1. A vaccine composition including a heat-inactivated poxvirus.

2. The vaccine composition of claim 1, wherein said vaccine composition induces interferon in a recipient upon administration of said vaccine composition.

3. The vaccine composition of claim 1, wherein said heat-inactivated poxvirus comprises a vaccinia virus.

4. The vaccine composition of claim 2, wherein said heat-inactivated poxvirus comprises a vaccinia virus.

5. The vaccine composition of claim 1, further comprising a mixture of said heat-inactivated poxvirus and one or more of a live vaccine vector and a non-replicating vaccine component.

6. The vaccine composition of claim 5, wherein said heat-inactivated poxvirus comprises a vaccinia virus.

7. A method for preparation of a vaccine, comprising the step of adding a heat-inactivated poxvirus to said vaccine prior to administration to a vaccine recipient.

8. The method of claim 7, wherein said heat-inactivated poxvirus comprises vaccinia virus.

9. The method of claim 7, further comprising adding one or more of a live vaccine vector and a non-replicating vaccine component to said vaccine.

10. A vaccination method, comprising administering a vaccine composition including a heat-inactivated poxvirus to an animal or human.

11. The vaccination method of claim 10, wherein said heat-inactivated poxvirus comprises a vaccinia virus.

12. The vaccination method of claim 10, further comprising a mixture of said heat-inactivated poxvirus and one or more of a live vaccine vector and a non-replicating vaccine component.